Tetra Radar · FDA Approvals · Decision date
UGN-103: FDA decision date
UroGen Pharma Ltd. (URGN) · 14 June 2027
Our NDA for UGN-103 for the treatment of adults with recurrent low-grade intermediate risk NMIBC is presently under review by FDA with a PDUFA target action date of June 14, 2027.
Source: 10-Q of 4 November 2026
The decision is pending.
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.